COVID-19 KASALLIGINI BOSHDAN KECHIRGAN METABOLIK SINDROM BILAN OG’RIGAN BEMORLAR KLINIK-BIOKIMYOVIY KO‘RSATKICHLARINING RETROSPEKTIV TAHLILI
##article.subject##:
metabolik sindrom, COVID-19, uglevod va lipid almashinuvi, triglitserid-glyukoza indeksi##article.abstract##
Gipertoniya, semizlik va qandli diabet bilan og'rigan bemorlarda koronavirus kasalligi (COVID-19) tufayli kelib chiqadigan asoratlar rivojlanish xavfi yuqori hisoblanadi.
Tadqiqotning maqsadi COVID-19 ni boshidan kechirgan bemorlarda lipid spektri va uglevod almashinuvini retrospektiv tahlil qilishdan iborat.
Materiallar va usullar: 2022-yilning yanvar oyidan avgust oyigacha bo’lgan davrda RIIATEMda davolangan va ma’lumotlar bazasiga kiritilgan 215 nafar bemorning klinik ma’lumotlari retrospektiv tahlil qilindi. SARS-CoV-2 virusiga polimeraza zanjir reaksiyasi (PZR-test) usuli yordamida tasdiqlangan va kasallik tarixida COVID-19 tashxisi qo’yilgan 127 nafar bemorning 88 nafari koronavirus infeksiyasi bilan og‘rimagan. Keyinchalik, tana vazn indeksi (TVI), qon bosimi, qondagi triglitseridlar (TG), umumiy xolesterin (UX), glyukoza, insulin va C-reaktiv oqsil (CRO) miqdorlari haqida ma’lumotlar mavjud bo‘lmagan bemorlarning kasallik tarixlari tahlildan chiqarib tashlandi.
Olingan natijalar: COVID-19 bilan kasallanmagan biroq MS bilan og’rigan bemorlarga yoki MS bilan o'grimagan, COVID-19ni boshidan kechirgan shaxslarga nisbatan, COVID-19ni boshdan kechirgan va metabolik sindrom (MS) bilan og'rigan bemorlar gemodinamikasida (yuqori SAQB), lipid almashinuvida (triglitseridlar, Apo B, ApoB/ApoA1ning yuqori miqdorlari hamda kam miqdordagi YuZLP va Apo A1), uglevod almashinuvida (och qoringa glyukoza, insulin va HOMA-IRning yuqori ko‘rsatkichlari) sezilarli o‘zgarishlar, shuningdek, yallig‘lanish markeri bo‘lgan C-reaktiv oqsili (CRO) miqdorining oshishi kuzatildi.
Библиографические ссылки
Abbasian M., Ebrahimi H., Delvarianzadeh M. et al. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016; 10(3): 132-136. doi: 10.1016/j.dsx.2016.01.003.
Ansari-Moghaddam A., Adineh H., Zareban I., Farmanfarma K. Prevalence of metabolic syndrome and population attributable risk for cardiovascular, stroke, and coronary heart diseases as well as myocardial infarction and all-cause mortality in middle-east: Systematic review & meta-analysis. Obesity Medicine. 2019; 14: 100086. doi: 10.1016/j.obmed.2019.100086.
Arhipova E.V. Metabolicheskij sindrom: patogenez, kriterii diagnostiki i lechenie. Vestnik Buryatskogo gosudarstvennogo universiteta. Medicina i farmaciya. 2019; 2: 3‒9. doi: 10.18101/2306-1995-2019-2-3-9
Buber I., Nar R., Kaya D. et al. Assessment of triglyceride/glucose index with respect to coronary slow flow. Bratisl Lek Listy. 2022; 123(8): 585-588. doi: 10.4149/BLL 2022 095.
Chen L., Lin Z., Chen J. et al. Can elevated concentrations of ALT and AST predict the risk of 'recurrence' of COVID-19? Epidemiol Infect. 2020 Sep 21;148: e218. DOI: 10.1017/S0950268820002186
Chowdhury M., Anik A., Farhana Z. et al. Prevalence of metabolic syndrome in Bangladesh: a systematic review and meta-analysis of the studies. BMC Public Health. 2018; 18(1): 308. doi: 10.1186/s12889-018-5209-z.
Demidova T.YU., Izmajlova M.YA., Belova K.M. Rol' trigliceridno-glyukoznogo indeksa v opredelenii serdechno-sosudistogo i metabolicheskogo prognoza u pacientov s saharnym diabetom 2-go tipa. Medicinskij sovet. 2023; 17(9): 47–57. doi.org/10.21518/ ms2023-172.
Farmanfarma K., Kaykhaei M., Mohammadi M. et al. The Prevalence and Trend of Metabolic Syndrome in the South-East of Iran. J Med Life. 2020; 13(4): 587-599. doi: 10.25122/jml-2020-0052.
Hussain A., Bhowmik B., do Vale Moreira N. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020; 162: 108142. doi: 10.1016/j.diabres.2020.108142.
Khan S., Sobia F., Niazi N. et al. Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance. Diabetol Metab Syndr. 2018; 10: 74. doi: 10.1186/s13098-018-0376-8.
Lee S., Han K., Kang Y. et al. Trends in the prevalence of metabolic syndrome and its components in South Korea: Findings from the Korean National Health Insurance Service Database (2009-2013). PLoS One. 2018; 13(3): e0194490. doi: 10.1371/journal.pone.0194490.
Li B., Yang F., Zhao J.et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020; 109(5): 531–538. doi: 10.1007/s00392-020-01626-9.
Li G., Chen Z., Lv Z. et al. Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. Int J Endocrinol. 2021; 1:7394378. doi: 10.1155/2021/7394378.
Najdenova A.G., Simeonov M.M., Atanasov A.M. i dr.Issledovanie associacii sootnoshenij mezhdu ApoB/ApoA1, TS/HDL-C, LDL-C/HDL-C i trigliciridami/ HDL-S i metabolicheskim sindromom v bolgarskoj populyacii. Evrazijskij Soyuz Uchenyh. 2016; 5(26): 52-60.
Nedogoda S.V., Ledyaeva A.A., Salasyuk A.S. i dr. Vliyanie perenesennogo COVID-19 na elastichnost' sosudov i funkciyu pecheni u pacientov s izbytochnoj massoj tela. Profilakticheskaya medicina. 2023; 26(2): 69–78. doi.org/10.17116/profmed20232602169
Scuteri A., Laurent S., Cucca F. et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015; 22(4): 486-491. doi: 10.1177/2047487314525529.
Tahani Masoud, Nasab Shiva Rakhshani, Shahramian Iraj et al. GGT Level as a New Biomarker of COVID-19 Infection; a Systematic Review and Meta-Analysis Comparing Intensive Care Unit (ICU) Patients with Non-ICU Cases. Infekc. bolezni (Infectious Diseases). 2023; 21(2): 47–56. (In Russian). doi: 10.20953/1729-9225-2023-2-47-56.
Yuksel Y., Yildiz C. Evaluation of triglyceride-glucose index in coronary slow flow patients. Kardiologiia. 2023; 63(5): 62-67. doi: 10.18087/cardio.2023.5.n2296.
Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8):727–733. doi: 10.1056/nejmoa2001017.
